These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1068 related articles for article (PubMed ID: 33630146)
1. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer. Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146 [TBL] [Abstract][Full Text] [Related]
2. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer. Sun M; Lu D; Li X; Wang J; Zhang L; Yang P; Yang Y; Shen J Cancer Med; 2024 Sep; 13(18):e70216. PubMed ID: 39302034 [TBL] [Abstract][Full Text] [Related]
3. Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983 [TBL] [Abstract][Full Text] [Related]
5. Li Y; Wu X; Huang Y; Bian D; Jiang L Ann Nucl Med; 2020 May; 34(5):314-321. PubMed ID: 32088884 [TBL] [Abstract][Full Text] [Related]
6. Usefulness of Li Y; Li Y; Huang Y; Wu X; Yang Z; Wu C; Jiang L Ann Nucl Med; 2021 Sep; 35(9):1048-1057. PubMed ID: 34101153 [TBL] [Abstract][Full Text] [Related]
7. Associations between detectable circulating tumor DNA and tumor glucose uptake measured by Ottestad AL; Johansen H; Halvorsen TO; Dai HY; Wahl SGF; Emdal EF; Grønberg BH BMC Cancer; 2023 Jul; 23(1):646. PubMed ID: 37434111 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
9. Primary tumor standardized uptake value (SUVmax) measured on Hui Z; Wei F; Ren H; Xu W; Ren X J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919 [TBL] [Abstract][Full Text] [Related]
10. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy. Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of 18 F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer. Li D; Tan X; Yuan H; Yao X; Sun X; He L; Jiang L Nucl Med Commun; 2023 Apr; 44(4):309-317. PubMed ID: 36756769 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of the Volumetric Parameters of Dual-Time-Point Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426 [No Abstract] [Full Text] [Related]
13. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer. Bian J; Yan K; Liu N; Xu X J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of metabolic tumor volume of pretreatment Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476 [TBL] [Abstract][Full Text] [Related]
15. New insight on the correlation of metabolic status on Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013 [TBL] [Abstract][Full Text] [Related]
16. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Satoh Y; Onishi H; Nambu A; Araki T Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640 [TBL] [Abstract][Full Text] [Related]
17. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281 [TBL] [Abstract][Full Text] [Related]
18. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer. Hu WD; Wang HC; Wang YB; Cui LL; Chen XH Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535 [TBL] [Abstract][Full Text] [Related]
19. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Chen HH; Chiu NT; Su WC; Guo HR; Lee BF Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]